|
FDA approval for the drug, Citalopram–Celexa, in the US was given on
July 17 in 1998 and the manufacturer of this pill is the Forest
labs. In the brain, information passes from one neuron to another
through the synapse, a space between two neurons where the neuron
that sends information release of neurotransmitters. These
neurotransmitters are then captured by the receiving neuron
receptors of information, which transmits itself information by the
same process of neurons in neurons. About 10% of neurotransmitters
released are lost in the process.
Depression is linked to a lack of stimulation of receptor neuron. To
stimulate SSRIs inhibit serotonin reuptake. Indeed, it remains
longer in the synaptic cleft, increasing the chances of being
recognised by the receiving neuron. The SSRIs are described as
selective because they act only on the pumps reuptake of serotonin
officials, as opposed to other antidepressants, which affect other
neurotransmitters. The sale of Citalopram is not prohibited since it
has undergone several clinical trials and experimental treatment the
future of Celexa seems bright.
There is a common belief in certain doctors prescribe the medication
too easily even psychiatrists in cases where their use is not the
main indication and where the effects may be positive on lifestyles.
They believe that the systematic chemical therapeutic response
Citalopram consists of is very useful and helpful. Others feel that
the so called causes of depression, which provide the basis for the
prescription of SSRIs, are not been established scientifically, and
that Celexa mechanisms are not yet adequately understood.
|
